CTLA4 and breast cancer: As TNBC is more likely to respond to immunotherapy than other breast cancer subtypes, we found a group of TNBC patients who may respond to immune checkpoint inhibitors, especially TNBC patients with PD-1 and CTLA4 upregulation in the immune subtype.